Nicotinamide mononucleotide (NMN) has become one of the most widely studied NAD+ precursors in longevity research, yet a strange paradox sits at the heart of its pharmacology: the molecule is largely degraded before it ever reaches systemic circulation, and yet animal and human studies consistently show that oral NMN raises tissue NAD+ levels. Resolving this paradox requires looking past simple absorption numbers and into the specific transporters, tissue compartments, and metabolic interconversions that govern how NMN actually gets to the cells that need it.
What Is NMN?
Nicotinamide mononucleotide is a 334-Da nucleotide composed of a nicotinamide base, a ribose sugar, and a phosphate group. It sits one enzymatic step upstream of nicotinamide adenine dinucleotide (NAD+) in the salvage pathway: the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase) converts NMN directly into NAD+ by adding an AMP moiety. Because NAD+ itself cannot efficiently cross cell membranes, the body relies on smaller precursors — nicotinamide (NAM), nicotinamide riboside (NR), and NMN — to replenish intracellular NAD+ pools that decline with age.[1]
The interest in NMN as a therapeutic precursor stems from work in the laboratory of Shin-ichiro Imai at Washington University, which demonstrated that long-term oral NMN administration mitigates age-associated physiological decline in mice without observable toxicity.[2] The clinical question that followed was deceptively simple: how does an oral phosphorylated nucleotide actually deliver NAD+ precursor to peripheral tissues?
How NMN Pharmacokinetics Work
First-Pass Degradation: Orally administered NMN encounters multiple barriers before reaching systemic circulation. The phosphate group makes the intact molecule too polar to cross enterocyte membranes by passive diffusion. In the gut lumen and at the brush border, CD73 (ecto-5′-nucleotidase) dephosphorylates a substantial fraction of NMN to nicotinamide riboside, which is then either absorbed as NR or further cleaved to nicotinamide by purine nucleoside phosphorylase. This means that much of what is delivered as “NMN” reaches the portal circulation as NR or NAM rather than as intact NMN.[3]
The Slc12a8 Transporter: In 2019, Grozio and colleagues identified Slc12a8 as a specific NMN transporter expressed strongly in the small intestine, particularly the jejunum. Slc12a8 transports intact NMN into enterocytes in a sodium-dependent manner, with rapid uptake kinetics that allow NMN to elevate intracellular NAD+ within minutes. This was a controversial but important finding because it suggested that at least a fraction of oral NMN does not require dephosphorylation to enter cells, and that intestinal NAD+ pools themselves may be a relevant target.[4]
The NMN–NR–NMN Cycle: Once across the enterocyte or hepatocyte membrane (in whatever molecular form), the precursors interconvert rapidly. NR is phosphorylated back to NMN intracellularly by nicotinamide riboside kinases (NRK1 and NRK2), and NMN is converted to NAD+ by NMNAT. The functional consequence is that route-of-degradation does not necessarily equate to loss of bioactivity — the carbon skeleton of NMN may reach the cell as NR and be reconverted to NMN inside the cytoplasm.[3]
Tissue Distribution: Following oral dosing in mice, isotope-labeled NMN raises NAD+ in liver most rapidly, followed by kidney, pancreas, and adipose tissue. Skeletal muscle and brain show slower and more modest increases, reflecting both blood–tissue barrier kinetics and the dependence of these tissues on circulating NAM and NR rather than direct NMN uptake.[2]
Clinical Evidence
Human Bioavailability: Irie and colleagues conducted the first single-dose human pharmacokinetic study of oral NMN in 2020, administering 100, 250, and 500 mg to healthy men. Plasma metabolites of NMN — predominantly nicotinamide and methylnicotinamide — rose in a dose-dependent fashion, confirming that oral NMN enters systemic NAD+ metabolism. The study did not measure intact plasma NMN, consistent with the expectation that most circulating precursor exists as downstream metabolites.[5]
NAD+ Restoration in Humans: Yoshino and colleagues subsequently demonstrated in a randomized placebo-controlled trial that 10 weeks of 250 mg/day oral NMN in postmenopausal women with prediabetes improved muscle insulin sensitivity and altered the muscle transcriptome in pathways related to insulin signaling and muscle remodeling. Importantly, this trial established that an orally bioavailable dose — despite extensive first-pass metabolism — produces measurable tissue-level effects on insulin signaling, indirectly supporting that NAD+ pools in target tissues are being replenished.[6]
Delivery Route Comparisons: Sublingual and intranasal routes have been proposed to bypass enterocyte degradation and CD73-mediated dephosphorylation, but published human pharmacokinetic data comparing routes remain limited. Intravenous NMN, used in some clinical protocols, achieves the highest peak plasma NMN concentrations but the actual half-life of intact circulating NMN is short — on the order of minutes — because plasma CD73 and tissue uptake rapidly clear it.[3]
Safety Profile
Across published human trials, oral NMN at doses ranging from 100 to 1250 mg/day has been well tolerated, with no consistent signal of clinically significant adverse events. The Irie single-ascending-dose study found no abnormal changes in heart rate, blood pressure, oxygen saturation, or laboratory parameters at doses up to 500 mg.[5] The Yoshino 10-week trial at 250 mg/day similarly reported no serious adverse events and no significant changes in body weight, blood pressure, liver enzymes, or kidney function.[6]
The theoretical concerns with sustained NAD+ precursor loading center on the methylation burden of nicotinamide clearance (each NAM molecule consumes one methyl group via NNMT to form methylnicotinamide) and on the possibility of preferentially fueling NAD+-dependent processes in unwanted cell populations. Neither concern has produced a clear clinical signal in human trials to date, but both remain reasons to favor intermittent or modest dosing schedules rather than continuous high-dose loading.
NMN vs Other NAD+ Precursors
NMN vs Nicotinamide Riboside (NR): NR is smaller, uncharged, and crosses membranes more readily than NMN, with established human pharmacokinetic profiles showing dose-proportional increases in whole-blood NAD+. Because much of orally administered NMN is converted to NR in the gut lumen, NR may be considered the more pharmacologically direct precursor in some compartments. NMN, however, may have advantages in tissues where Slc12a8 is highly expressed and where direct NMN uptake bypasses the rate-limiting NRK phosphorylation step.[3]
NMN vs Nicotinamide (NAM): NAM is the cheapest and most bioavailable precursor but it directly inhibits sirtuins at higher concentrations and imposes a methyl-group cost during clearance. NMN sits one step further along the salvage pathway and avoids the sirtuin-inhibitory plasma concentrations associated with high-dose NAM.
NMN vs Niacin (Nicotinic Acid): Niacin uses a separate enzymatic route (the Preiss–Handler pathway) and reliably elevates NAD+ but produces vasodilatory flushing through GPR109A activation. NMN does not cause flushing because it does not engage this receptor.
The practical synthesis of the pharmacokinetic literature is that no single precursor is universally superior — the optimal choice depends on which tissue compartment is being targeted, what dose is feasible, and what delivery route is available. For systemic NAD+ restoration via the oral route, the differences between NMN and NR in humans appear smaller than the differences between any precursor and placebo.
References
- Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.” Cell Metabolism. 2018;27(3):529-547.
- Mills KF, Yoshida S, Stein LR, et al. “Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.” Cell Metabolism. 2016;24(6):795-806.
- Yoshino J, Baur JA, Imai SI. “NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.” Cell Metabolism. 2018;27(3):513-528.
- Grozio A, Mills KF, Yoshino J, et al. “Slc12a8 is a nicotinamide mononucleotide transporter.” Nature Metabolism. 2019;1(1):47-57.
- Irie J, Inagaki E, Fujita M, et al. “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.” Endocrine Journal. 2020;67(2):153-160.
- Yoshino M, Yoshino J, Kayser BD, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021;372(6547):1224-1229.
